Skip to content
Open access

394. Association of COVID-19 vaccination with improved treatment adherence in patients with schizophrenia: a nationwide propensity score-matched cohort study

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i152 - i153 · 0 citations

TL;DR

It is indicated that COVID-19 vaccination is safe in patients with schizophrenia and is not associated with an increased risk of psychiatric decompensation or treatment escalation, and vaccination was linked to improved treatment adherence, suggesting potential benefits beyond infection prevention.

Abstract

Abstract Background Individuals with schizophrenia face markedly elevated risks of SARS-CoV-2 infection, hospitalization, and mortality compared to the general population due to biological vulnerability, cognitive impairment, and socioeconomic disadvantage. Recognizing these risks, international public health guidelines have designated people with severe mental illness (SMI) as a high-priority group for COVID-19 vaccination. However, vaccine uptake among patients with schizophrenia has been suboptimal, partly due to structural barriers (e.g., limited access, institutional mistrust) and psychiatric concerns—including fears of symptom exacerbation, affective instability, or adverse interactions with psychotropic medications. While isolated case reports of psychiatric decompensation post-vaccination exist, large-scale real-world data on the clinical impact of COVID-19 vaccination in schizophrenia populations remain limited. Aims & Objectives We aimed to evaluate the association of COVID-19 vaccination with treatment adherence, psychiatric stability, and SARS-CoV-2 infection risk in patients with schizophrenia. Method We conducted a nationwide, retrospective, propensity score-matched cohort study using linked data from the National Health Insurance Service and the Korea Disease Control and Prevention Agency databases in South Korea. We identified patients with schizophrenia aged 19–64 years and stratified them into vaccinated (three doses) and unvaccinated groups. A 1:1 propensity score matching was performed. The primary outcomes were schizophrenia-related hospitalisation and emergency department visits. Key secondary outcomes included medication adherence, measured by the proportion of days covered (PDC), and diagnosed SARS-CoV-2 infection. Results Between December 1, 2019 and December 31, 2022, a total of 6,662 unvaccinated and 52,063 vaccinated patients were identified. After matching, the final cohort included 4,629 matched pairs (N=9,258). No significant between-group differences were observed in schizophrenia-related hospitalization or ED visit rates, suggesting that vaccination was not associated with psychiatric destabilization. However, the vaccinated group demonstrated significantly better medication adherence over time, with a smaller decline in PDC compared to the unvaccinated group (mean change –3.49% vs. –10.19%; adjusted p<0.0001). Paradoxically, the vaccinated group had a higher incidence of confirmed COVID-19 diagnoses (adjusted hazard ratio [aHR] for unvaccinated vs. vaccinated: 0.47, 95% CI: 0.439–0.504, p<0.0001), likely reflecting differences in healthcare access, testing frequency, or behavioral risk compensation. Discussion & Conclusions Our findings indicate that COVID-19 vaccination is safe in patients with schizophrenia and is not associated with an increased risk of psychiatric decompensation or treatment escalation. Importantly, vaccination was linked to improved treatment adherence, suggesting potential benefits beyond infection prevention—such as enhanced clinical continuity and engagement with care. These results support ongoing efforts to prioritize individuals with SMI in public health vaccination strategies and counter unfounded concerns about psychiatric risks. Targeted outreach and psychoeducation may further improve vaccine uptake and reduce disparities in this vulnerable population.

Read PDF

Similar papers

Sep 2026

Associations of Depressive Symptoms with COVID-19 Hospitalization or Death: The C4R Study.

The results support current CDC recommendations that depression be considered an underlying medical condition associated with higher risk for severe COVID-19 and suggest that increased clinical focus on risk mitigation for COVID-19 and other acute respiratory infections among patients with depressive symptoms is warran...

E. Oelsner, Yi-Fei Sun, P. Balte et al. · 0 citations
Open access Aug 2026

COVID-19 Vaccination and Risk of Post-COVID-19 Cardiovascular Disease: A Population-Based Cohort and Target Trial Emulation Study.

Findings support COVID-19 vaccination as an important component of strategies to reduce the burden of post-COVID-19 CVD while highlighting the need for further studies to clarify the mechanisms underlying these associations.

B. Seboka, D. Magliano, T. Marwick et al. · 0 citations
Open access Sep 2026

COVID-19 vaccine uptake among individuals with Down syndrome in the Unites States.

INTRODUCTION Individuals with Down syndrome are at increased risk for severe disease from acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, making them a priority group for COVID-19 vaccination. Data on vaccine uptake and factors associated with vaccination are needed to inform strategies to improve upta...

Nian Hui, T. Ding, Rees L. Lee et al. · 0 citations
Open access Sep 2026

Associations of age, COVID-19 vaccination, and SARS-CoV-2 infection history with health-related quality of life in a community-based longitudinal cohort in Singapore.

Older adults had lower HR-QoL across multiple domains, whereas younger participants showed lower HR-QoL primarily during the early post-infection period, whereas younger participants showed lower HR-QoL primarily during the early post-infection period.

Zhi-Lian Huang, Alexius Matthias Se Soh, Kang-Wei Zeng et al. · 0 citations
Open access Sep 2026

Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC).

Fatigue and functional performance improved over time regardless of vaccination status, and there was no statistically significant association between mRNA SARS-CoV-2 vaccination and worsening symptoms or impaired recovery.

Philipp Pries, J. Fuge, Michèle Scharbau et al. · 0 citations
Open access Aug 2026

Real-world antipsychotic prescribing patterns and mortality in schizophrenia: a registry cohort study from China

Abstract Aims Schizophrenia is a chronic psychiatric disorder associated with significantly elevated mortality. While antipsychotics are the cornerstone of treatment, their long-term effects on survival remain uncertain, particularly in non-Western populations. We aimed to assess the real-world association between anti...

Hongbo He, Lingyan Dai, Sicong Ma et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.